Changing the Treatment Paradigm in Cancer and Fibrotic Disease

learn more >


BLR Bio has a platform of assets targeted at specific diseases including cancer, fibrosis, and scarring.

The company also has unique CCN based diagnostic opportunities allowing for development in conjunction with one or more of the therapies or independently.

Our capabilities span drug discovery and early development stages to Phase 3 clinical trials. We anticipate that our product candidates will be partnered with pharmaceutical or biotechnology companies for advanced development and marketing. We endeavor to retain a participating role applying our development and commercialization capabilities.

BLR Bio is considering partnerships for individual or multiple disease areas, for therapy or and/or diagnostic applications and world-wide or in spceific geograpfical regions.

Please contact our business development group for additional information.

© BLR Bio, L.L.C. | 313 54th Street, Kenosha, WI, USA, 53140 |

Latest News

May 2016
"Dr. Bruce Riser, CEO of BLR Bio, was an invited speaker on Peptide Discovery, Preclinical and Clinical presented at the TIDES Oligonucleotide and Peptide Therapeutics Conference, at Long Beach. See selected pre-interview."

April 2016
"BLR Bio was selected as one of the top 50 emerging biotechnology companies to present at the MedCity INVEST, Health Tech Showcase in Chicago April 10-12."

see news archives »


April 2016
Balanced Regulation of the CCN Family of Matricellular Proteins: A Novel Approach to the Prevention and Treatment of Fibrosis and Cancer.
Journal of Cell Communication and Signaling 9.4 (2015): 327–339.
PMC. Web. 28 Apr. 2016.

more publications »